Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI

Executive Summary

The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.

You may also be interested in...



Pfizer’s Big Bet On Arena Pays Off With First Phase III Win For Etrasimod In UC

The company will present detailed data in the future, but top-line results show statistically significant improvement over placebo at 12 weeks in ulcerative colitis, an increasingly competitive market.

AbbVie Grows Gastrointestinal Business With Rinvoq Approval In UC

Along with Skyrizi’s expected approval in Crohn’s, AbbVie says Rinvoq in ulcerative colitis is key to its Humira sales erosion strategy. It is Rinvoq’s third US supplemental approval since December.

Gossamer Hopes To Stand Out In Crowded Spaces

The company plans to release topline results this year in ulcerative colitis and pulmonary arterial hypertension. In UC, especially, Gossamer is aiming for an opportunity that remains untapped.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel